Multidimensional analysis of endometriosis clinical trials based on the ClinicalTrials.gov database
10.12092/j.issn.1009-2501.2024.05.006
- VernacularTitle:基于ClinicalTrials.gov数据库的子宫内膜异位症临床研究多维度分析
- Author:
Baoyin ZHANG
1
;
Wenhui YANG
;
Qinglan LIU
;
Chen WANG
;
Jing WU
;
Qian LIU
;
Nan SUN
Author Information
1. 郑州大学第三附属医院药学部,郑州 450052,河南
- Keywords:
endometriosis;
clinical study registra-tion;
ClinicalTrials.gov;
multidimensional analysis
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2024;29(5):520-526
- CountryChina
- Language:Chinese
-
Abstract:
AIM:To perform a multidimensional analysis of the clinical study characteristics of endo-metriosis based on the ClinicalTrials.gov,providing comprehensive and objective information for re-searchers,clinicians,and clinical pharmacists.METHODS:A thorough investigation was conduct-ed on clinical trials related to endometriosis,regis-tered on the ClinicalTrials.gov from its inception to October 20,2023.Relevant trial data were extract-ed and statistically analyzed using bibliometrics and comparative research methods.RESULTS:A to-tal of 667 endometriosis clinical studies were regis-tered globally,showing an annual increase.The United States(127 trials),France(70 trials),and Ita-ly(57 trials)had the highest number of registered trials.Interventional studies were predominant(416 trials,62.4%),followed by observational stud-ies(251 trials,37.6%).Within interventional stud-ies,drug therapy was the primary intervention(223 trials,53.6%).Despite endometriosis being a female condition,male subjects were also consid-ered,with 6 trials specifically requiring male partici-pants and 37 trials not restricting gender.Compa-nies/corporations were the main funding sources,while public and governmental organizations pro-vided relatively less funding.CONCLUSION:Clinical trial research on endometriosis is in a phase of growth,with drug therapy being the main treat-ment approach.However,there is a relative lack of investment and attention from public funds and governmental organizations.
